Abstract YO31
Case summary
A 66-year-old male presented with left-sided pleuritic chest pain, common weak for 2 months and progressively increasing shortness of breath with dry cough for 1.5 months.On general survey, mild pallor was present, but there were no clubbing and palpable cervical and axillary lymph node. An X-ray showed a shadow in the left chest. The shadow of the heart was shifted to the right. Bronchoscopy showed compression of segmental bronchus of the left upper lobe bronchus. CT of the chest reveals a nodular pleura-based mass, which size was about 12.5х18.0х18.0 sm with effusion in the left pleural cavity. Around the nodular pleura-based mass were infiltrative changens. The histological analysis of tru-cut biopsy showed that there was fibrotic mesothelioma with necrosis or carcinoid. The patient underwent right upper lobectomy of lung with negative margins. During operation we saw that half of left pleural cavity was occupied by gigantic tumor, which size was 25x20x18 sm. Surface was bumpy, it had capsule, thick texture. There were effusion (150ml) in the left pleural cavity. The root of the lung, pericardium, thoracic part of aorta, diaphragm were free. The tumor was grew from right upper lobe (S5). The histological analysis after operation of this tumor showed that it was round cell sarcoma. After surgery, six cycles of adjuvant chemotherapy with ifosfamide and doxorubicin were given. Postadjuvant chemotherapy patient is kept on regular follow-up.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract